Stocks and InvestingStocks and Investing
Tue, April 12, 2022
Mon, April 11, 2022
Sun, April 10, 2022
Fri, April 8, 2022

Ami Fadia Maintained (BIIB) at Strong Buy with Decreased Target to $262 on, Apr 8th, 2022


Published on 2024-10-27 20:22:05 - WOPRAI, Ami Fadia
  Print publication without navigation


Ami Fadia of Needham, Maintained "Biogen Inc." (BIIB) at Strong Buy with Decreased Target from $290 to $262 on, Apr 8th, 2022.

Ami has made no other calls on BIIB in the last 4 months.



There are 16 other peers that have a rating on BIIB. Out of the 16 peers that are also analyzing BIIB, 11 agree with Ami's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Geoff Meacham of "B of A Securities" Maintained at Hold with Decreased Target to $225 on, Monday, March 28th, 2022
  • Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $223 on, Tuesday, March 8th, 2022
  • Mohit Bansal of "Wells Fargo" Maintained at Hold with Decreased Target to $235 on, Friday, February 4th, 2022
  • Evan Seigerman of "BMO Capital" Downgraded from Buy to Hold and Decreased Target to $238 on, Friday, February 4th, 2022
  • Carter Gould of "Barclays" Maintained at Hold with Decreased Target to $244 on, Thursday, January 20th, 2022
  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold and Decreased Target to $202 on, Thursday, January 13th, 2022
  • Salim Syed of "Mizuho" Maintained at Hold with Decreased Target to $207 on, Wednesday, January 12th, 2022
  • Laura Chico of "Wedbush" Maintained at Hold with Decreased Target to $195 on, Wednesday, January 12th, 2022
  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $216 on, Wednesday, January 12th, 2022
  • Cory Kasimov of "JP Morgan" Maintained at Hold with Decreased Target to $276 on, Tuesday, December 21st, 2021
  • Brian Skorney of "Baird" Maintained at Hold with Decreased Target to $258 on, Tuesday, December 21st, 2021


These are the ratings of the 5 analyists that currently disagree with Ami


  • Brian Abrahams of "RBC Capital" Upgraded from Hold to Buy and Increased Target to $248 on, Thursday, March 3rd, 2022
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $305 on, Monday, February 7th, 2022
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $330 on, Friday, February 4th, 2022
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $300 on, Monday, January 24th, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $270 on, Tuesday, January 18th, 2022